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Abstract. Critical to development of new therapies for Alzheimer’s disease (AD) is the ability to detect clinical or pathological
change over time. Clinical outcome measures typically used in therapeutic trials have unfortunately proven to be relatively variable
and somewhat insensitive to change in this slowly progressive disease. For this reason, development of surrogate biomarkers that
identify significant disease-associated brain changes are necessary to expedite treatment development in AD. Since AD pathology
is present in the brain many years prior to clinical manifestation, ideally we want to develop biomarkers of disease that identify
abnormal brain structure or function even prior to cognitive decline. Magnetic resonance imaging, fluorodeoxyglucose positron
emission tomography, new amyloid imaging techniques, and spinal fluid markers of AD all have great potential to provide
surrogate endpoint measures for AD pathology. The Alzheimer’s disease neuroimaging initiative (ADNI) was developed for
the distinct purpose of evaluating surrogate biomarkers for drug development in AD. Recent evidence from ADNI demonstrates
that imaging may provide more sensitive, and earlier, measures of disease progression than traditional clinical measures for
powering clinical drug trials in Alzheimer’s disease. This review discusses recently presented data from the ADNI dataset, and
the importance of imaging in the future of drug development in AD.
1. Introduction: A need for biomarkers of disease
in drug development
In the last two decades Alzheimer’s disease (AD) re-
search has made many leaps forward towards the goal
of finding a cure for AD. In particular, beta amyloid
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pathology and neurofibrillary tangles have been identi-
fied as highly associated with the clinical presentation
of AD [1,11]. And, an early onset AD clinical syn-
drome and pathology have been linked to autosomal
dominant kindreds with mutations in genes responsi-
ble for amyloid precursor protein metabolism. Anoth-
er important discovery was of the apolipoprotein ep-
silon 4 allele (APOE4), which is currently the most po-
tent known genetic risk for late onset AD [3]. Current
drug development strategies primarily focus on treat-
ing AD after cognitive symptoms have already begun,
after meeting clinical dementia criteria, or in clinical
prodromal states such as mild cognitive impairment
(MCI) [30,42]. However, unlike most diseases that
present shortly after the onset of underlying pathology,
we now realize that AD pathology begins many years
(possibly decades) prior to clinical manifestations [7,
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24]. And, once functional impairment occurs, it may be
difficult to derail the neurodegenerative process, mak-
ing it unlikely that we will be able to return individuals
to their pre-morbid cognitive state. Therefore, a cure
for Alzheimer’s disease is most likely to be found by
detecting Alzheimer’s disease pathology at its earliest
clinical stage, or potentially even before clinical man-
ifestations. For this, we need more sensitive measures
of clinical symptoms or underlying pathology to power
clinical trials.
Efforts to demonstrate disease-modifying effects in
AD have been frustratingly unsuccessful. While many
plausible targets and candidate agents have been de-
veloped, there have been no successful efficacy trials
(though several large trials are now in progress). In par-
ticular, failures of three putative anti-amyloid therapies
in AD, Flurizan, Alzemed and AN1792 underscored
the need to improve abilities to detect disease modify-
ing effects of putative AD therapies [38]. The failure
of completed trials to demonstrate benefits may reflect
low potency of the interventions, but it is quite likely
that methodological difficulties have contributed. In-
deed, there is a consensus that it is essential to improve
trial design to facilitate the development of the next
generation of AD therapies. Neuroimaging biomarkers
will be an important component of optimal trial design.
All of the AD drugs currently approved provide mod-
est symptomatic benefits that last twelve to eighteen
months, on average [43]. There is no evidence that
these drugs modify underlying disease pathology or
curtail the ultimate progression of disease and clini-
cal decline. Symptomatic improvement in cognition
and function or global status can be demonstrated in
3–6 month trials; maximal separation of treatment and
placebo groups on primary outcome measures occurs
in this time frame [43]. Because these effects can be
seen in a relatively short period of time, it has been fea-
sible to demonstrate benefits and select optimal doses
in Phase II trials that have been predictive of success in
pivotal Phase III studies of symptomatic therapies.
Disease-modifying drugs, however, will not nec-
essarily show any short-term symptomatic benefits.
These interventions, attacking targets along the amy-
loid or neurofibrillary tangle cascades or otherwise pro-
viding neuroprotection, aim to slow the rate of neurde-
generation causing cognitive and clinical decline. Un-
like symptomatic treatments, they are not particularly
aimed at “boosting” short term clinical performance.
Since there is often little or no placebo group decline
observed in mild AD trials of 6 months or less, long tri-
als are necessary to see an efficacy signal. Indeed, the
European Medicines Agency guidelines indicate that
trials of at least 18 months are required to document
disease-modifying effects. Dose-finding efficacy trials
are therefore not feasible in a standard-type 3-6 month
Phase II program.
This difficulty is compounded by the growing con-
cern that the mild AD population is too advanced in
terms of extent of amyloid and tangle neuropathology
to show substantial benefits with disease-modifying in-
terventions [38]. Pathology likely precedes dementia
onset by a decade or longer, with dementia onset rep-
resenting a late stage along the neurobiological path-
way [8,24]. For this reason, to optimize the impact
of disease-modifying treatments, they must be initi-
ated at the earliest possible stage of disease. But at
an early, pre-dementia stage of disease, decline rates
on standard cognitive and clinical measures are quite
gradual, reducing the power of trials to demonstrate
effects. Clinician-based assessments or cognitive mea-
sures such as the Alzheimer’s Disease Assessment
Scale (ADAS-Cog) [36] and the Clinical Dementia Rat-
ing Scale (CDR) [26], are commonly used to evaluate
treatment efficacy in such clinical trials, though both
are limited in their sensitivity to detect change over time
and require the use of large sample sizes and extend-
ed observation times [12,17,27]. To improve detec-
tion of significant treatment effects in early clinical or
pre-clinical disease, it is therefore necessary to develop
more sensitive surrogate endpoint measurer of disease
progression.
Neuroimaging biomarkers offer some solutions to
these difficulties. Longitudinal studies such as the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
have demonstrated the power of neuroimaging to re-
flect AD neurobiology [14,21,25,28]. It is now feasi-
ble to utilize neuroimaging to advance trial design in
three ways: to select early-stage subjects for trials, to
provide covariates to reduce unexplained variance in
cognitive and clinical progression and thereby increase
trial power, and as surrogate outcome measures.
The studies reviewed here represent analyses of
imaging and spinal fluid data collected in the AD-
NI, and obtained from the publicly available ADNI
database (http://www.loni.ucla.edu\ADNI). The AD-
NI was launched in 2003 by the National Institute
on Aging (NIA), the National Institute of Biomedi-
cal Imaging and Bioengineering (NIBIB), the Food
and Drug Administration (FDA), private pharmaceuti-
cal companies and non-profit organizations, as a $60
million, 5-year public-private partnership. The prima-
ry goal of ADNI has been to test whether serial mag-
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netic resonance imaging (MRI), positron emission to-
mography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined
to measure the progression of mild cognitive impair-
ment (MCI) and early Alzheimer’s disease (AD). De-
termination of sensitive and specific markers of very
early AD progression is intended to aid researchers and
clinicians to develop new treatments and monitor their
effectiveness, as well as lessen the time and cost of
clinical trials. The Principle Investigator of this initia-
tive is Michael W. Weiner, M.D., VA Medical Center
and University of California – San Francisco. ADNI
is the result of efforts of many co-investigators from a
broad range of academic institutions and private cor-
porations, and subjects have been recruited from over
50 sites across the US and Canada. The initial goal of
ADNI was to recruit 800 adults, ages 55 to 90, to par-
ticipate in the research – approximately 200 cognitive-
ly normal older individuals to be followed for 3 years,
400 people with MCI to be followed for 3 years, and
200 people with early AD to be followed for 2 years.
For up-to-date information see www.adni-info.org.
2. Neuroimaging and subject selection
Attempts to study disease-modifying interventions
at a clinical stage earlier than mild dementia have gen-
erally focused on MCI [30,42]. The population de-
fined by commonly used guidelines for MCI is some-
what heterogeneous; it includes individuals who may
not show substantial decline during the years follow-
ing diagnosis. Further, rate of progression to demen-
tia has varied substantially among various MCI stud-
ies [32]. Neuroimaging and cerebrospinal biomarker
studies such as ADNI and those at Washington Uni-
versity and the University of Guthenburg have clari-
fied the neurobiological events underlying AD and its
prodromal stages. Evidence suggests that amyloid de-
position occurs years before dementia onset, and after
a lag period without significant symptoms, amnestic
MCI develops with gradual progression to AD [14]. It
therefore seems reasonable to select subjects with the
cognitive criteria of MCI plus biomarker evidence of
amyloid as an ideal population for pre-dementia trials
of disease-modifying drugs, particularly anti-amyloid
drugs [6]. Cerebral spinal fluid (CSF) biomarkers and
recent amyloid imaging techniques may provide an op-
portunity to enrich subject selection in nearly treatment
trials.
ADNI data provides an opportunity to test this
idea [13,28]. Subjects with brain amyloid can be iden-
tified either by amyloid PET imaging [19,29] (either
with 11C-PIB [18] or the newer 18F amyloid ligands) or
by the presence of a low CSF amyloid beta 42 (Aβ42)
level [39]. Since more ADNI subjects have had CSF
collection than amyloid imaging, our group has ex-
plored the value of subject selection based on levels
of CSF amyloid. We find a substantial gain in sta-
tistical power, as expected. For an MCI study with
a two year treatment period aiming to demonstrate a
40% slowing of disease progression as indicated by
decline on continuous measures of cognition or clini-
cal stage, selection of subjects with CSF amyloid lev-
el cut-offs reduces the necessary sample size by 35%.
Similarly, such selection reduces sample size of an
MCI study using a time-to-dementia analysis, yielding
a 30% reduction in sample size [4,5] (http://www.adni-
info.org/images/stories/SteeringCommittee2009/03-1
adni%20early%20ad%20trial.pdf). Likewise, it may
also be possible to preselect subjects for clinical trials
based on degree of amyloid present on amyloid PET
imaging. Evidence suggests from ADNI that PiB pos-
itivity is associated with worsened episodic memory
and hippocampal volumes in MCI subjects [25], and
may indicate higher rates of conversion to AD. Utiliz-
ing these biomarkers to reduce sample sizes needed to
demonstrate drug effects on clinical measure will make
studies of treatment effects in MCI readily feasible.
Further, it is obviously appropriate to limit subjects in
anti-amyloid treatment trials to those with evidence of
amyloid accumulation.
3. Neuroimaging and covariates for analysis of
standard outcome measures
Amyloid imaging and CSF Aβ measurements iden-
tify subjects with amyloid dysregulation and accumu-
lation, but do not show significant longitudinal change
in subjects with MCI or AD [7,14]. On the oth-
er hand, volumetric MRI measures, including hip-
pocampal volume, whole brain volume, ventricular en-
largement and regional cortical thickness measures,
show predictable longitudinal decline that tracks clin-
ical progression [14–16,23]. Likewise, measures of
flurodeoxyglucose (FDG) PET, a measure of glucose
metabolisms also reflect stage of clinical disease, as
demonstrated in the ADNI cohort [22]. This provides
an accurate and objective measure of disease stage,
which in turn predicts subsequent cognitive and clini-
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cal decline. It is therefore useful to utilize volumetric
MRI measures or FDG PET as covariates in the anal-
ysis of longitudinal data from MCI and AD trials [22,
44]. For example, we assessed various ADNI imaging
and biomarker measures as covariates to identify their
influence on required sample sizes in a 24 month clini-
cal trial of MCI, utilizing decline on the ADAS-cog12
or the Clinical Dementia Rating Scale – sum of boxes
(CDR-SB) as efficary endpoint measures. Using linear
random effect modeling we assumed a 30% effect size
with a power of 80% and a 2-sided alpha equal to 0.05.
If just utilizing decline on the ADAS-cog12 as an end-
point measure, it would require 593 subjects to detect
a 30% effect size. If cortical thickness in the temporal
lobe is added as a covariate to this model, this num-
ber can be reduced by 10% to 534 (http://www.adni-
info.org/images/stories/SteeringCommittee2009/03-1
adni%20early%20ad%20trial.pdf). Further evaluation
of how various imaging techniques can be used as co-
variates in endpoint modeling may prove to enhance
our ability to detect drug effects and reduce necessary
sample sizes and study lengths.
4. Neuroimaging for trial endpoints
A surrogate endpoint is a marker of underlying dis-
ease that reflects clinical and/or pathological disease
processes with a high degree of specificity and sensitiv-
ity. For a biomarker to be accepted as a surrogate end-
point in a clinical drug trial it must (1) be correlated with
the clinical endpoint; and (2) fully capture the net effect
of the intervention on the clinical efficacy endpoint [10,
31]. The regulatory agencies require demonstration of
benefits on two co-primary outcome measures for ap-
proval of treatments for AD, a broad cognitive measure
plus an assessment of global clinical status or function.
As noted above, it requires a large trial to demonstrate
such effects in AD and especially in pre-dementia pop-
ulations. However, the effect of an intervention on
synaptic function (presumably underlying the cognitive
and clinical changes) can be assessed using FDG-PET,
providing a potential method for exploring benefit in
smaller studies. This has been utilized in a small Phase
1 study of a neuroprotective intervention in mild to
moderate AD [40], and may have wider utility across
the spectrum of disease [33–35]. Reiman et al, demon-
strated that the ADNI FDG-PET dataset can be utilized
to improve power to detect disease progression and dis-
ease modifying treatment effects when used as a prima-
ry treatment effect endpoint (presented at the 2009 AD-
NI meeting, April 27th, Seattle, WA: http://www.adni-
info.org/images/stories/SteeringCommittee2009/06
jagust.pdf). A training dataset consisting of baseline
to 12 month follow-up FDG-PET scans from 27 AD
subjects from the ADNI dataset was used to optimize
settings for the detection of longitudinal FDG-PET sig-
nal decline. This was done by creating an empirically
defined statistical region of interest (sROI) that iden-
tifies brain voxels whose mean change serves as a re-
liable index for decline in FDG PET signal over 12
months (Fig. 1). Utilizing a second testing dataset (29
AD), mean change in this pre-defined sROI was used
as a primary outcome measure for a power analysis to
determine detectable change over 12 months in ADNI
AD subjects. This power analysis assumed a treatment
effect size of 25%, 80% power with an alpha=0.05. To
identify significant changes in FDG PET signal consis-
tent with those seen in AD, only 61 AD patients would
be required in a 12 month study. This is compared to
673 subjects for similar effects to be recognized with
decline in CDR-SB, 612 with the ADAS-cog11, or 493
for change in Mini Mental State Exam Scores in this
same cohort.
Both MRI volumetric endpoints and FDG PET mea-
sures may be useful for improving power in clinical
trials or even used as primary outcome measures. MRI
is more specific for establishing a disease-modifying
treatment effect. FDG-PET, on the other hand, can
show reversible symptomatic effects as well as disease-
modifying effects. Analysis of ADNI data demon-
strates that MRI data is also substantially more pow-
erful than cognitive endpoints, providing a feasible
method for exploring effects in Phase II trials, and
for establishing disease-modifying effects in Phase III
studies.
MRI volumetric measures have been well established
to distinguish Alzheimer’s disease and MCI from non-
demented individuals, as well as predict future cogni-
tive decline [14,16,37,41]. Recently, ADNI data has
provided an opportunity to assess potential uses of vol-
umetric MRI data as primary outcome measures in mul-
ticenter randomized clinical trials, and determine pow-
er for detecting change over time. In an ADNI volu-
metric MRI study by our group [20], we characterized
12-month whole brain atrophy rates in 34 probable AD
patients (pAD), 75 amnestic MCI patients, and 38 el-
derly NC using Iterative Principal Component Analysis
(IPCA). Using IPCA [2], whole brain atrophy annual
percent change was determined to be 0.60 ± 0.23%
in pAD patients, 0.37 ± 0.28% in MCI patients, and
0.28 ± 0.24% in NC (ANOVA P = 1e-6, linear trend
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Fig. 1. Statistical pattern of FDG PET change over 12 months in AD sample. Statistical region of interest representing 12 month FDG PET signal
change in a training set of 27 subjects from the ADNI dataset. This pattern of AD-like change can be used as an outcome measure to identify
effects of putative treatments for AD in randomized clinical trials.
P = 7e-7). For pAD, power estimates determined the
need for 37 patients using this measure of brain atro-
phy, compared to 474 using the ADAS-COG to detect
a 25% AD-slowing treatment effect with 80% power
and two-tailed P = 0.05 in twelve-month multi-center
randomized controlled trials (RCTs).
Thompson et al. recently used the ADNI MRI dataset
to demonstrate that tensor based morphometry (TBM),
a sensitive technique that measures volumetric changes
in brain structures, can be used as an endpoint measure
to significantly improve effect sizes and reduce sample
sizes in clinical trials evaluating disease modifying ef-
fects [12]. Applying the sROI approach introduced by
Reiman et al (Fig. 1), this study exemplifies the areas
of change over time in AD (n = 104), MCI (n = 254),
and normal controls (157). Detection power was great-
ly enhanced by summarizing changes in a statistically-
defined region-of-interest derived from an independent
training sample of 22 AD patients. In power analyses,
the best method required only 48 AD and 88 MCI sub-
jects to give 80% power to detect a 25% reduction in
the mean annual change using a two-sided test (at α =
0.05). This represents a dramatic sample size reduc-
tion compared to using clinical scores as outcome mea-
sures (619 AD/6797 MCI for the ADAS-Cog, and 408
AD/796 MCI for the Clinical Dementia Rating sum-of-
boxes scores). Table 1 compares sample size estimates
using FDG-PET, TBM-MRI, whole-brain atrophy and
clinical measures as primary endpoint measures for a
hypothetical clinical drug trial in AD, compiled from
the studies presented here. It is not clear which imag-
ing technique provides the most power to detect AD-
associated brain changes over time. More studies are
needed. However, it is clear that using imaging as pri-
Table 1
Treatment trial sample size estimates using
FDG PET and MRI morphometry compared to










Estimated sample size per treatment arm in a
treatment trial for Alzheimer’s disease needed to
detect a 25% reduction in mean annual change
with a two-sided test andα= 0.05 at 80% power
(pooled data, see text). *Adapted from [12].
mary endpoints provides advantages compared to using
standard cognitive endpoint measures in clinical trials
of AD.
Many investigators suspect that the ideal population
for disease-modifying interventions is the group with
amyloid accumulation but no significant symptomatol-
ogy. Cognitive and clinical measures are not useful in
assessing drug effects in this “pre-symptomatic” group.
But based on preliminary evidence from ADNI, such
subjects do show increased atrophy rates, as well as
changes in FDG PET and amyloid imaging,so it may be
possible to demonstrate drug effects using these imag-
ing measures. It must be emphasized though that until
treatment effects on such measures are shown to cor-
relate with cognitive and clinical measures, they will
not be considered primary (ie, surrogate) endpoints for
pivotal trials. Nevertheless, as of now, these types of
correlations are most promising for MRI volumetrics
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and FDG PET [9,14,21,23]. Amyloid PET imaging
also holds great promise for measuring therapeutic ef-
fects on cortical amyloid load for treatments that direct-
ly target amyloid pathology. Although the ADNI is not
designed to assess how well biomarkers capture inter-
vention effects, it is well positioned to give researches
opportunities to develop surrogate biomarkers for this
purpose.
5. Conclusion
Improvements to clinical trial methodology will fa-
cilitate the development of disease-modifying treat-
ments for AD. In particular, neuroimaging modalities
offer a method for subject selection and characteriza-
tion that can greatly improve statistical power. This
is critically important for trials in AD dementia, and
even more crucial for trials conducted in mildly im-
paired, pre-dementia populations with very gradual de-
cline rates. Analysis of the publically available ADNI
data has confirmed the utility of imaging biomarkers for
trial design; such analyses provide a framework for the
incorporation of standardized neuroimaging measures
into multicenter trials. Adoption of these methods by
drug development programs can link treatment effect
on neuroimaging measures to standard cognitive and
clinical outcomes, the essential step toward the goal
of establishing neuroimaging biomarkers as surrogate
primary endpoints in AD clinical trials to facilitate the
development of treatments for pre-symptomatic indi-
viduals.
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